Showing 1 - 10 results of 10 for search 'Mark R. Kelley', query time: 0.03s
Refine Results
-
1
-
2
-
3
-
4
APE1/Ref-1 as a Therapeutic Target for Inflammatory Bowel Disease by Lauren Sahakian, Ainsley M. Robinson, Linda Sahakian, Rhian Stavely, Mark R. Kelley, Kulmira Nurgali
Published 2023-10-01
Article -
5
-
6
-
7
-
8
Drug Inhibition of Redox Factor-1 Restores Hypoxia-Driven Changes in Tuberous Sclerosis Complex 2 Deficient Cells by Jesse D. Champion, Kayleigh M. Dodd, Hilaire C. Lam, Mohammad A. M. Alzahrani, Sara Seifan, Ellie Rad, David Oliver Scourfield, Melissa L. Fishel, Brian L. Calver, Ann Ager, Elizabeth P. Henske, David Mark Davies, Mark R. Kelley, Andrew R. Tee
Published 2022-12-01
Article -
9
Inhibition of PRMT5 by market drugs as a novel cancer therapeutic avenue by Lakshmi Prabhu, Matthew Martin, Lan Chen, Özlem Demir, Jiamin Jin, Xiumei Huang, Aishat Motolani, Mengyao Sun, Guanglong Jiang, Harikrishna Nakshatri, Melissa L. Fishel, Steven Sun, Ahmad Safa, Rommie E. Amaro, Mark R. Kelley, Yunlong Liu, Zhong-Yin Zhang, Tao Lu
Published 2023-01-01
Article -
10
New Ref-1/APE1 targeted inhibitors demonstrating improved potency for clinical applications in multiple cancer types by Silpa Gampala, Hye-ran Moon, Randall Wireman, Jacqueline Peil, Sonia Kiran, Dana K. Mitchell, Kylee Brewster, Henry Mang, Andi Masters, Christine Bach, Whitney Smith-Kinnamen, Emma H. Doud, Ratan Rai, Amber L. Mosley, Sara K. Quinney, D. Wade Clapp, Chafiq Hamdouchi, James Wikel, Chi Zhang, Bumsoo Han, Millie M. Georgiadis, Mark R. Kelley, Melissa L. Fishel
Published 2024-03-01
Article